Literature DB >> 32800850

Palmitate induces human glomerular mesangial cells fibrosis through CD36-mediated transient receptor potential canonical channel 6/nuclear factor of activated T cell 2 activation.

Yong Su1, Qingqing Chen2, Yinghui Ju3, Weizu Li4, Weiping Li5.   

Abstract

BACKGROUND: Our previous study suggested that palmitate (PA) induces human glomerular mesangial cells (HMCs) fibrosis. However, the mechanism is not fully understood. Recent studies suggested that transient receptor potential canonical channel 6 (TRPC6)/nuclear factor of activated T cell 2 (NFAT2) played an important role in renal fibrosis. Moreover, cluster of differentiation 36 (CD36) regulated the synthesis of TPRC6 agonist diglyceride. In the present study, we investigated whether PA induced HMCs fibrosis via TRPC6/NFAT2 mediated by CD36.
METHODS: A type 2 diabetic nephropathy (DN) model was established in Sprague Dawley rats, and HMCs were stimulated with PA. Lipid accumulation and free fatty acid (FFA) uptake were measured. The expression levels of TGF-β1, p-Smad2/3, FN, TRPC6, NFAT2 and CD36 were evaluated. The intracellular calcium concentration ([Ca2+]i) was assessed.
RESULTS: FFA were elevated in type 2 DN rats with kidney fibrosis in addition to NFAT2 and CD36 expression. In vitro, PA induced HMCs fibrosis, [Ca2+]i elevation and NFAT2 activation. SKF96365 or TRPC6-siRNA could attenuate PA-induced HMCs damage. By contrast, the TRPC6 activator showed the opposite effect. Moreover, NFAT2-siRNA also suppressed PA-induced HMCs fibrosis. CD36 knockdown inhibited the PA-induced [Ca2+]i elevation and NFAT2 expression. In addition, long-term treatment with PA decreased TRPC6 expression in HMCs.
CONCLUSION: The results of this study demonstrated that PA could induce the activation of the [Ca2+]i/NFAT2 signaling pathway through TRPC6, which led to HMCs fibrosis. Although activation of TRPC6 attributed to CD36-mediated lipid deposition, long-term stimulation of PA may lead to negative feedback on the expression of TPRC6.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD36; Fibrosis; NFAT2; Palmitate; TRPC6

Mesh:

Substances:

Year:  2020        PMID: 32800850     DOI: 10.1016/j.bbalip.2020.158793

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  3 in total

1.  Klotho Ameliorates Podocyte Injury through Targeting TRPC6 Channel in Diabetic Nephropathy.

Authors:  Xingmei Yao; Hengjiang Guo; Mengyao Sun; Sixuan Meng; Bingbing Zhu; Ji Fang; Jiebo Huang; Hao Wang; Lina Xing
Journal:  J Diabetes Res       Date:  2022-04-18       Impact factor: 4.061

2.  Benzothiazole Amides as TRPC3/6 Inhibitors for Gastric Cancer Treatment.

Authors:  Yingjie Wei; Mengxian Zhang; Zhenbin Lyu; Guolin Yang; Tian Tian; Mingmin Ding; Xiaodong Zeng; Fuchun Xu; Pengyu Wang; Fangfang Li; Yixuan Liu; Zhengyu Cao; Jing Lu; Xuechuan Hong; Hongbo Wang
Journal:  ACS Omega       Date:  2021-03-24

3.  NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury.

Authors:  Zhi-Yong Xie; Wei Dong; Li Zhang; Meng-Jie Wang; Zhen-Meng Xiao; Yu-Hua Zhang; Wan-Xin Shi; Ying Huang; Yan Yang; Cui-Li Li; Lei Fu; Xing-Chen Zhao; Rui-Zhao Li; Zhi-Lian Li; Yuan-Han Chen; Zhi-Ming Ye; Shuang-Xin Liu; Zheng Dong; Xin-Ling Liang
Journal:  Acta Pharmacol Sin       Date:  2021-12-22       Impact factor: 7.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.